{
    "root": "25889190-6fc5-4767-8882-e4f89a126fd4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Montelukast Sodium",
    "value": "20250527",
    "ingredients": [
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CHERRY",
            "code": "BUC5I9595W"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MONTELUKAST SODIUM",
            "code": "U1O3J18SFL"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SODIUM PHOSPHATE, TRIBASIC",
            "code": "A752Q30A6X"
        }
    ],
    "indications": "Montelukast sodium is a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 12 months of age and older ( 1.1 ). Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older ( 1.2 ). Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 6 months of age and older.  Reserve use for patients who have an inadequate response or intolerance to alternative therapies ( 1.3 ). Limitations of Use: Not indicated to treat an acute asthma attack ( 5.2 ).",
    "contraindications": "Administration (by indications): Asthma: Once daily in the evening for patients 12 months and older ( 2.1 ). Acute prevention of EIB:  One tablet at least 2 hours before exercise for patients 6 years of age and older ( 2.2 ). Seasonal allergic rhinitis: Once daily for patients 2 years and older ( 2.3 ) Perennial allergic rhinitis: Once daily for patients 6 months and older ( 2.3 ). Dosage (by age): 15 years and older: one 10-mg tablet ( 2 ). 6 to 14 years: one 5-mg chewable tablet ( 2 ). 2 to 5 years: one 4-mg chewable tablet or one packet of 4-mg oral granules ( 2 ). 6 to 23 months: one packet of 4-mg oral granules ( 2 ). Patients with both asthma and allergic rhinitis should take only one dose daily in the evening ( 2.4 ). For oral granules: Must administer within 15 minutes after opening the packet (with or without mixing with food) ( 2.5 ).",
    "warningsAndPrecautions": "Montelukast sodium oral granules USP, 4 mg, are white to off white granules with 500 mg net weight, packed in a child-resistant foil packet. They are supplied as follows:\n                  NDC 13668-531-11  unit packet\n                  NDC 13668-531-94  carton with 30 packets.\n                  For Montelukast sodium film-coated tablets 10 mg\n                  The tablets are available as follow:\n                   Montelukast sodium tablets USP, 10 mg, are light brown colored, round, biconvex film coated tablets debossed with \"1081\" on one side and \"10 MG\" on other side. They are supplied as follows:\n                  \n                  Bottles of 30                               NDC 13668-081-30\n                  Bottles of 90                               NDC 13668-081-90\n                  Bottles of 500                             NDC 13668-081-05\n                  Bottles of 3,200                           NDC 13668-081-32\n                  For Montelukast sodium chewable tablets USP 4 mg and 5 mg\n                  The tablets are available as follow:\n                   Montelukast sodium chewable tablets USP, 4 mg, are pink colored, oval biconvex shaped, uncoated tablets, debossed with '1079' on one side and '4 MG' on other side. They are supplied as follows:\n                  \n                  Bottles of 30                               NDC 13668-079-30\n                  Bottles of 90                               NDC 13668-079-90\n                  Bottles of 500                             NDC 13668-079-05\n                  Montelukast sodium chewable tablets USP, 5 mg, are pink colored, round shaped, uncoated tablets, debossed with '1080' on one side and '5 MG' on other side. They are supplied as follows:\n                  \n                  Bottles of 30                               NDC 13668-080-30\n                  Bottles of 90                               NDC 13668-080-90\n                  Bottles of 500                             NDC 13668-080-05\n                  \n                     Storage\n                  \n                  Store montelukast sodium 4-mg oral granules, montelukast sodium 4-mg chewable tablets, 5-mg chewable tablets and 10-mg film-coated tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.",
    "adverseReactions": "Hypersensitivity to any component of montelukast sodium ( 4 )."
}